A Phase 3 interventional study of Immunoglobulin in Primary Immune Deficiency Disorder, sponsored by Green Cross Corporation. Withdrawn. Open to participants aged 24 Months to 203 Months. Per ClinicalTrials.gov, last updated 2020-07-07.
Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the safety, efficacy, and pharmacokinetics of IGIV-SN in pediatric subjects with primary immunodeficiency humoral diseases (PHID)
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
Biological: Immunoglobulin
Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
Also known as: IGIV-SN
Efficacy: Incidence of Acute SBIs (Serious Bacterial Infections)
The incidence of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess
Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)
Safety: Overall Incidence of AEs that occur during 72 hours of following an infusion of test drug
The overall incidence of adverse events (AEs) that occur during or within 1 hours, 24 hours, and 72 hours following an infusion of test product, regardless of whether or not the AE is determined to be product related
Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)
Efficacy: Incidence of Infections other than acute serious bacterial infections
Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)
Safety: The frequency of all AEs that occuring during the study
(regardless of the casual relationship)
Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)
PK Endpoint (1)
Plasma Concentration-Time Curve (PK Parameters of Total IgG)
Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)
PK Endpoint (2)
Area Under the Curve (PK Parameters of Total IgG)
Time frame: 13 months (12 months of treatment + 1 month of Follow-Up)
No study locations are listed for this record.
Ran from Apr 2019 to primary completion in Apr 2019, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins
Primary Immunodeficiency Diseases →